Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
批准号:
8604175
负责人:
Dikoma C Shungu
金额:
$49.9万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-09 至 2016-12-31
关键词:
AddressAgeAntioxidantsBiological MarkersBody FluidsCase StudyCerebrospinal FluidCerebrovascular CirculationCharacteristicsChronic Fatigue SyndromeClinicalClinical ResearchClinical assessmentsCluster AnalysisComorbidityComplexControl GroupsCoupledDataDevelopmentDiagnosisDiagnostic testsDiseaseEquilibriumFatigueFunctional disorderGlutathioneHeadacheHealthHeterogeneityLifeMagnetic ResonanceMagnetic Resonance ImagingMagnetic Resonance SpectroscopyMajor Depressive DisorderMeasurementMeasuresMental disordersMetabolismModelingMusculoskeletal PainNatureOutcome MeasureOxidation-ReductionOxidative StressPatientsPhysiologicalPhysiologyPilot ProjectsPlasmaProtonsPublishingResearch PersonnelRestSample SizeSamplingScientific Advances and AccomplishmentsSeriesShort-Term MemorySleep disturbancesSomatization DisorderSore ThroatSpecificitySpin LabelsStratificationStressSubgroupSymptomsSystemTechniquesTestingTissuesUncertaintyUrineVentricularbasecohortdisorder controlevidence baseexpectationfunctional disabilityin vivoindexingmultidisciplinaryneuroimagingneuropsychiatrynew therapeutic targetoxidative damagepublic health relevancesextrend
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Chronic fatigue syndrome (CFS) is a complex multi-system disorder, which is often misdiagnosed as a psychiatric illness. As a result, the diagnosis of CFS is highly controversial. Discovery of CFS-specific biomarkers that can differentiate the disorder from phenotypically similar psychiatric conditions, such as major depressive disorder (MDD), could thus have a profound impact, not only for how the disorder is generally perceived and managed, but also for the development of objective diagnostic tests, for identification of new therapeutic targets, as well as for advancing scientific understanding of CFS. Recently, using advanced magnetic resonance neuroimaging techniques and a standardized battery of clinical assessments in 15 patients with CFS with those in 15 patients with MDD and in 13 healthy controls, the applicants discovered strong experimental evidence, including a mean deficit of 36% in the most abundant antioxidant in living tissue, glutathione (GSH), increased ventricular cerebrospinal fluid (CSF) lactate, and decreased regional cerebral blood flow (rCBF) compared to controls, which suggested increased oxidative stress as a pathophysiological model of CFS. However, while highly promising and intrinsically consistent, both the validity and the specificity of this oxidative stress hypothesis for CFS remain uncertain, as (a) the essential findings of the study have yet to be replicated, and (b) the same types of abnormalities were found in MDD compared to controls. On the other hand, with comparisons revealing trend-level differences between CFS and MDD, the investigators hypothesized that limited sample size, coupled with the inherent clinical heterogeneity of the two disorders, likely limited the power of their pilot study to detect potential differences between the two disorders. Therefore, to address this potential limitation and to attempt objective differentiation of CFS and MDD - a daunting and continuing challenge - the investigators propose: (1) to replicate in larger cohorts the results of
their pilot neuroimaging study that suggested the oxidative stress hypothesis of CFS; (2) to extend the support and evidence base for the model through measurements of several established markers of oxidative stress in plasma, urine and CSF samples from all the subjects; (3) to correlate the resulting objective outcome measures with clinical indices of overall health and functional disability in all subjects; and (4) to attempt to decrease the inherent clinical heterogeneity in both the CFS and MDD groups through stratification or subtyping techniques based on clinical variables that are unique to each disorder, and then to compare the outcome measures between the resulting subgroups. The expectation is that this approach would identify subgroups of CFS and MDD patients between which significant differences in outcome measures exist that can enable objective differentiation of the two disorders, thereby establishing the outcome measures as bona fide diseases biomarkers, and supporting oxidative stress as a valid and specific pathophysiological model for CFS.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
-
批准号:10394929
-
项目类别:
-
资助金额:$58.31万
-
财政年份:2020
-
负责人:Dikoma C Shungu
-
依托单位:
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
-
批准号:10210456
-
项目类别:
-
资助金额:$58.31万
-
财政年份:2020
-
负责人:Dikoma C Shungu
-
依托单位:
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
-
批准号:9982469
-
项目类别:
-
资助金额:$58.63万
-
财政年份:2020
-
负责人:Dikoma C Shungu
-
依托单位:
Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement
-
批准号:10617658
-
项目类别:
-
资助金额:$58.31万
-
财政年份:2020
-
负责人:Dikoma C Shungu
-
依托单位:
Oxidative Stress and Neuroinflammation: Co-conspirators in ME/CFS Pathophysiology
-
批准号:10237223
-
项目类别:
-
资助金额:$17.88万
-
财政年份:2017
-
负责人:Dikoma C Shungu
-
依托单位:
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
-
批准号:8461041
-
项目类别:
-
资助金额:$49.9万
-
财政年份:2013
-
负责人:Dikoma C Shungu
-
依托单位:
Specificity and Validity of Oxidative Stress Model of Chronic Fatigue Syndrome
-
批准号:9016576
-
项目类别:
-
资助金额:$49.43万
-
财政年份:2013
-
负责人:Dikoma C Shungu
-
依托单位:
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
-
批准号:8302655
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2012
-
负责人:Dikoma C Shungu
-
依托单位:
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
-
批准号:8662799
-
项目类别:
-
资助金额:$20.37万
-
财政年份:2012
-
负责人:Dikoma C Shungu
-
依托单位:
2/2-Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
-
批准号:8501688
-
项目类别:
-
资助金额:$19.48万
-
财政年份:2012
-
负责人:Dikoma C Shungu
-
依托单位:
NAC for Treatment of Oxidative Stress in Chronic Fatigue Syndrome
-
批准号:8402234
-
项目类别:
-
资助金额:$26.95万
-
财政年份:2012
-
负责人:Dikoma C Shungu
-
依托单位:
NAC for Treatment of Oxidative Stress in Chronic Fatigue Syndrome
-
批准号:8512796
-
项目类别:
-
资助金额:$19.92万
-
财政年份:2012
-
负责人:Dikoma C Shungu
-
依托单位:
N-Acetylcysteine for Neuroprotection in Parkinson's Disease
-
批准号:8332243
-
项目类别:
-
资助金额:$22.06万
-
财政年份:2011
-
负责人:Dikoma C Shungu
-
依托单位:
N-Acetylcysteine for Neuroprotection in Parkinson's Disease
-
批准号:8228344
-
项目类别:
-
资助金额:$24.41万
-
财政年份:2011
-
负责人:Dikoma C Shungu
-
依托单位:
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
-
批准号:8046446
-
项目类别:
-
资助金额:$49.55万
-
财政年份:2007
-
负责人:Dikoma C Shungu
-
依托单位:
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
-
批准号:7265580
-
项目类别:
-
资助金额:$41.94万
-
财政年份:2007
-
负责人:Dikoma C Shungu
-
依托单位:
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
-
批准号:7409133
-
项目类别:
-
资助金额:$42.45万
-
财政年份:2007
-
负责人:Dikoma C Shungu
-
依托单位:
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
-
批准号:7821324
-
项目类别:
-
资助金额:$51.21万
-
财政年份:2007
-
负责人:Dikoma C Shungu
-
依托单位:
Novel MRS Neurotechnology for Imaging GABA & Glutamate Function in Schizophrenia
-
批准号:7585187
-
项目类别:
-
资助金额:$48.92万
-
财政年份:2007
-
负责人:Dikoma C Shungu
-
依托单位:
CONSOLE UPGRADE FOR A 4.23 T WHOLE-BODY MR SYSTEM
-
批准号:6053629
-
项目类别:
-
资助金额:$48.2万
-
财政年份:2000
-
负责人:Dikoma C Shungu
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: